Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:EU EMA/INS/GCP/126568/2023 - Annual Report of the Good Clinical Practice (GCP) Inspectors' Working Group (IWG) 2022 2023 3.1.2 - ComCompliance

From GxPlex

Revision as of 15:06, 29 June 2026 by gxplex>GxPlexBot (Import from GxPlex Excel)
Jump to: navigation, search



Document information
Reference EU EMA/INS/GCP/126568/2023

- Annual Report of the Good Clinical Practice (GCP) Inspectors' Working Group (IWG) 2022 2023

Validity area EU
Scope(s) G
Document name EMA/INS/GCP/126568/2023

- Annual Report of the Good Clinical Practice (GCP) Inspectors' Working Group (IWG) 2022

Version / Revision 2023
Status Current
Document type Official guideline
Language(s) EN
Description EMA/INS/GCP/164938/2024

Inspections Office Quality and Safety of Medicines Department

Annual Report of the Good Clinical Practice (GCP) Inspectors' Working Group (IWG) 2023 Adopted by the GCP IWG on 26 November 2024

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Scope G
Document part 3.1.2 - ComCompliance
Language EN
Original entry by Florian Adragna
Contributors
Tags (EN)
Tags (original language)
Tags (FR)
Comment Examples of critical and major compliance findings

Content

Examples of critical and major findings in the sub-categories of the three main categories "General", "Trial Management", and "Investigational Site" are listed below. [...] Investigational Site

Protocol Compliance (Others) • Appropriate measures were not taken to keep the investigator personnel blinded to trial participant treatment assignment. • Not all investigations/trial visits for trial participants were performed as specified in the trial protocol. • Treatment of a trial participant with prohibited medication.

Protocol Compliance (Safety Reporting) • Reporting of serious adverse events not done within the 24-hour timeline. • Classification of "life threatening" adverse event as non-serious. • Several potential adverse events collected by the clinical nurses or by oncologist residents in the electronic medical records were not collected, assessed or reported in the trial eCRF.

Protocol Compliance (Selection Criteria) • Inclusion of trial participants not meeting eligibility criteria. • A patient was considered eligible while failing one exclusion criterion. Although the examination performed on randomisation day met the acceptance criteria, the patient should have been considered a screen failure considering that rescreening was not allowed in this trial. [...]